---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008734"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:44:01.158127+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid reports Q1 net loss $16.1M, revenue $1.4M; OV329 IND on track for Q4 2022

## Summary
- Net loss $16.1M ($0.23/sh) vs net income $176M in Q1 2021 on one-time Takeda payment.
- Revenue fell to $1.4M from $208.4M; current revenue from Marinus and Healx license fees.
- Cash and equivalents $166.7M expected to fund pipeline into 2025.
- IND for OV329 (GABA aminotransferase inhibitor) planned in Q4 2022 to start Phase 1.
- Non-GAAP adjusted operating expenses were $14.2M; total operating expenses $17.7M.

## SEC filing metadata
- accession: 0000950170-22-008734
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000095017022008734/0000950170-22-008734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000095017022008734/ovid-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008734
- JSON: https://secwatch.observer/filing/0000950170-22-008734.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008734.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.